- Conditions
- Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
- Interventions
- BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly
- Drug
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma
- Interventions
- BI-505, High dose melphalan, Autologous stem cell transplantation
- Biological · Other
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- BI-505
- Biological
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Salt Lake City, Utah
- Conditions
- Atherosclerosis
- Interventions
- MLDL1278A, placebo, statin, stable dose
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 22
- States / cities
- Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma
- Interventions
- BI-1206, Rituximab, Acalabrutinib
- Biological
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Louisville, Kentucky
- Conditions
- Solid Tumor, Adult
- Interventions
- BI1206
- Drug
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Denver, Colorado • Saint Paul, Minnesota + 2 more